Pharmagen, Inc. (PHRX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharmagen, Inc. (PHRX) with AI Score 55/100 (Hold). Pharmagen, Inc. distributes specialty drugs and pharmaceuticals to healthcare providers in the United States. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Pharmagen, Inc. (PHRX) Healthcare & Pipeline Overview
Pharmagen, Inc. is a US-based distributor of specialty drugs, blood plasma derivatives, and pharmaceuticals to hospitals and healthcare facilities. The company also manufactures and distributes health supplements, including Clotamin, catering to specific patient needs. Pharmagen operates within the competitive medical distribution sector, focusing on specialized and hard-to-find products.
Investment Thesis
Pharmagen, Inc. operates in the niche market of specialty pharmaceutical distribution, focusing on hard-to-find drugs and plasma derivatives. With a small market capitalization of $0.00B and negative P/E ratio, the company presents a high-risk, high-reward investment profile. Key value drivers include the company's ability to maintain strong gross margins (63.3%) and its specialized product offerings like Clotamin. Growth catalysts include potential expansion into new geographic markets or therapeutic areas. However, investors should be aware of the risks associated with OTC-traded companies and Pharmagen's negative profit margin of -134.2%.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 63.3% indicates strong pricing power in its specialty drug distribution.
- The company's Beta of 0.24 suggests lower volatility compared to the overall market.
- Pharmagen's focus on specialty drugs and plasma derivatives caters to a niche market with specific medical needs.
- The company's distribution network serves hospitals, acute care facilities, and surgery centers across the United States.
- Pharmagen manufactures and distributes Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin.
Competitors & Peers
Strengths
- Specialized product offerings (specialty drugs, plasma derivatives).
- Proprietary health supplement (Clotamin).
- Established distribution network.
- High gross margin (63.3%).
Weaknesses
- Small market capitalization.
- Negative profit margin (-134.2%).
- OTC-traded stock.
- Limited financial resources.
Catalysts
- Upcoming: Potential expansion of Clotamin distribution through new partnerships.
- Ongoing: Strategic partnerships with healthcare providers to become a preferred supplier.
- Ongoing: Efforts to develop new specialty drug formulations.
- Ongoing: Potential acquisition of complementary businesses to expand product portfolio.
Risks
- Potential: Intense competition in the pharmaceutical distribution industry.
- Potential: Regulatory changes and compliance requirements.
- Potential: Supply chain disruptions.
- Potential: Economic downturn affecting healthcare spending.
- Ongoing: Limited financial disclosure due to OTC listing.
Growth Opportunities
- Expansion of Clotamin Distribution: Pharmagen has the opportunity to expand the distribution of Clotamin, its specialized over-the-counter multivitamin for patients on Warfarin. The market for dietary supplements is projected to reach $86.1 billion by 2027, offering a significant growth avenue. Pharmagen can leverage its existing distribution network and marketing efforts to increase Clotamin sales and market share. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Pharmagen can pursue strategic partnerships with hospitals, acute care facilities, and surgery centers to become a preferred supplier of specialty drugs and pharmaceuticals. By offering customized solutions and value-added services, Pharmagen can strengthen its relationships with key customers and secure long-term contracts. The market for pharmaceutical distribution is estimated at $1 trillion globally. Timeline: Ongoing.
- Geographic Expansion within the United States: Pharmagen can expand its geographic reach within the United States by targeting underserved markets and establishing new distribution centers. By increasing its presence in key regions, Pharmagen can enhance its ability to serve customers and capture a larger share of the market. The US pharmaceutical market is the largest in the world, valued at over $500 billion. Timeline: 2-3 years.
- Development of New Specialty Drug Formulations: Pharmagen can leverage its expertise in drug formulation to develop new specialty drug products that address unmet medical needs. By investing in research and development, Pharmagen can create proprietary products that differentiate it from competitors and generate higher profit margins. The global market for specialty drugs is projected to reach $640 billion by 2027. Timeline: 3-5 years.
- Acquisition of Complementary Businesses: Pharmagen can pursue acquisitions of complementary businesses, such as specialty pharmacies or pharmaceutical manufacturers, to expand its product portfolio and market reach. By acquiring companies with synergistic capabilities, Pharmagen can create economies of scale and enhance its competitive position. The M&A market in the pharmaceutical industry is highly active, with numerous opportunities for strategic acquisitions. Timeline: Ongoing.
Opportunities
- Expansion of Clotamin distribution.
- Strategic partnerships with healthcare providers.
- Geographic expansion within the United States.
- Development of new specialty drug formulations.
Threats
- Intense competition in the pharmaceutical distribution industry.
- Regulatory changes and compliance requirements.
- Supply chain disruptions.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Specialized product offerings, including hard-to-find pharmaceuticals.
- Proprietary health supplement, Clotamin.
- Established relationships with healthcare providers.
- Expertise in drug formulation.
About PHRX
Pharmagen, Inc., formerly known as Sunpeaks Ventures, Inc., was established in January 2013 and is headquartered in Silver Spring, Maryland. The company operates as a distributor of specialty drugs and pharmaceuticals, serving hospitals, acute care facilities, surgery centers, and other healthcare practitioners across the United States. Pharmagen's core business involves sourcing and distributing a range of specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. These products cater to diverse medical needs, including treatments for cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, blood disorders, hepatitis, and HIV. In addition to its distribution activities, Pharmagen manufactures and distributes health supplements, notably Clotamin, a specialized over-the-counter multivitamin dietary supplement formulated for patients on Warfarin. The company also offers traditional pharmaceuticals, such as antibiotics and vaccines, to its distribution customers, and specializes in drug formulation.
What They Do
- Distributes specialty drugs to hospitals and healthcare facilities.
- Sources and distributes blood plasma derivatives.
- Offers specialty products for treating respiratory, oncology, and cardiovascular conditions.
- Provides vaccines and anti-infectives.
- Manufactures and distributes health supplements, including Clotamin.
- Specializes in the formulation of drugs.
- Sells traditional pharmaceuticals, such as antibiotics and injectables.
Business Model
- Pharmagen generates revenue by distributing specialty drugs and pharmaceuticals to healthcare providers.
- The company also earns revenue from the sale of its manufactured health supplements, such as Clotamin.
- Pharmagen's business model focuses on sourcing hard-to-find pharmaceuticals and providing specialized services to its customers.
Industry Context
Pharmagen, Inc. operates within the medical distribution industry, which is characterized by increasing demand for specialty pharmaceuticals and biologics. The market is driven by an aging population, rising prevalence of chronic diseases, and advancements in medical treatments. The industry is highly competitive, with major players focusing on supply chain efficiency, product diversification, and strategic partnerships. Pharmagen differentiates itself by focusing on specialty drugs, hard-to-find pharmaceuticals, and manufacturing its own health supplements. The company's success depends on its ability to navigate complex regulatory requirements, maintain strong relationships with suppliers and customers, and adapt to evolving market trends.
Key Customers
- Hospitals
- Acute care facilities
- Surgery centers
- Healthcare practitioners
Financials
Chart & Info
Pharmagen, Inc. (PHRX) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Sep 23, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHRX.
Price Targets
Wall Street price target analysis for PHRX.
MoonshotScore
What does this score mean?
The MoonshotScore rates PHRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mackie A. Barch
CEO
Mackie A. Barch is the CEO of Pharmagen, Inc. His background includes experience in managing and overseeing the distribution of specialty drugs and pharmaceuticals. He has been instrumental in guiding the company's strategic direction and growth initiatives. His leadership focuses on expanding Pharmagen's product portfolio, strengthening its distribution network, and enhancing its relationships with healthcare providers. He manages a team of 24 employees at Pharmagen.
Track Record: Under Mackie A. Barch's leadership, Pharmagen, Inc. has focused on expanding its specialty drug offerings and developing its proprietary health supplement, Clotamin. He has overseen the company's efforts to navigate the complex regulatory landscape and maintain compliance with industry standards. His strategic decisions have aimed at improving the company's financial performance and increasing its market share.
PHRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharmagen, Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks are not subject to the same stringent listing standards, resulting in less transparency and potentially higher volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight compared to exchange-listed stocks.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory actions.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with OTC investing.
- The company has been in operation since 2013.
- Pharmagen distributes products to hospitals and healthcare facilities.
- The company manufactures and distributes its own health supplement (Clotamin).
PHRX Healthcare Stock FAQ
What does Pharmagen, Inc. do?
Pharmagen, Inc. is a distributor of specialty drugs and pharmaceuticals to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes a range of specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. In addition to its distribution activities, Pharmagen manufactures and distributes health supplements, notably Clotamin, a specialized over-the-counter multivitamin dietary supplement formulated for patients on Warfarin. The company also offers traditional pharmaceuticals, such as antibiotics and vaccines, to its distribution customers, and specializes in drug formulation.
What do analysts say about PHRX stock?
As of March 16, 2026, there is no readily available analyst coverage for Pharmagen, Inc. (PHRX), likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC stocks. Key valuation metrics, such as P/E ratio, may not be meaningful due to the company's negative profitability. Growth considerations include the company's ability to expand its product offerings and distribution network.
What are the main risks for PHRX?
The main risks for Pharmagen, Inc. include intense competition in the pharmaceutical distribution industry, regulatory changes and compliance requirements, supply chain disruptions, and economic downturn affecting healthcare spending. Additionally, as an OTC-traded stock, PHRX faces risks related to limited financial disclosure, low trading volume and liquidity, higher price volatility, and potential for fraud or manipulation. Investors should carefully consider these risks before investing in PHRX.
What revenue streams does Pharmagen, Inc. have in healthcare?
Pharmagen, Inc.'s revenue streams primarily consist of sales from specialty drugs, blood plasma derivatives, and traditional pharmaceuticals to hospitals, acute care facilities, surgery centers, and healthcare practitioners. A secondary revenue stream is generated from the sale of their manufactured health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement. The specific breakdown of revenue by product line and therapeutic area is not publicly available.
How does Pharmagen, Inc. navigate regulatory approval processes?
As a distributor of pharmaceuticals, Pharmagen, Inc. must comply with regulations set forth by the FDA and other regulatory bodies. While the company does not directly manufacture prescription drugs requiring extensive clinical trials and approval processes, it must ensure that its sourcing, storage, and distribution practices adhere to strict quality control standards. Pharmagen also manufactures and distributes the health supplement Clotamin, which is subject to regulations governing dietary supplements. The company's specific track record and pending approvals are not publicly available.
What are the key factors to evaluate for PHRX?
Pharmagen, Inc. (PHRX) currently holds an AI score of 55/100, indicating moderate score. Key strength: Specialized product offerings (specialty drugs, plasma derivatives).. Primary risk to monitor: Potential: Intense competition in the pharmaceutical distribution industry.. This is not financial advice.
How frequently does PHRX data refresh on this page?
PHRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PHRX's recent stock price performance?
Recent price movement in Pharmagen, Inc. (PHRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product offerings (specialty drugs, plasma derivatives).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- Financial data may not be up-to-date or readily verifiable.